A Biobehavioral Intervention for Latino/Hispanic Young Adults with Cancer
Launched by UNIVERSITY OF CALIFORNIA, IRVINE · Mar 23, 2024
Trial Information
Current as of August 21, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new therapy called Goal-focused Emotion-Regulation Therapy (GET) to see how it helps Latino/Hispanic young adults who have survived cancer. The goal is to reduce feelings of distress, improve how they handle their emotions, and teach them better ways to achieve their goals. Participants in the study will be randomly assigned to either receive GET or a similar support program called Instrumental Supportive Listening (ISL) over the course of eight weeks. Researchers will check in with participants at various times to see how they are feeling and to measure certain health markers.
To be eligible for this trial, participants need to be between 18 and 39 years old, identify as male, and have been diagnosed with cancer between the ages of 15 and 39. They should also be fluent in English or Spanish and have certain levels of distress or goal navigation skills. The trial is currently recruiting participants, and anyone who is interested should be aware that there are some health conditions that might prevent them from joining. This study aims to provide valuable insights that could help improve support for young adult cancer survivors in the future.
Gender
MALE
Eligibility criteria
- Inclusion Criteria:
- • Age 18 to 39 years at time of consent
- • Male gender; self-identified
- • A confirmed diagnosis of cancer (any stage)
- • Diagnosed with cancer between the ages of 15 and 39
- • Hispanic/Latino identification
- • A score ≤ 1.8 on the Goal Navigation Scale or ≥ 4 on the Distress Thermometer
- • English or Spanish fluency
- Exclusion Criteria:
- • lifetime history of bipolar disorder, schizophrenia, schizoaffective disorder (self-report)
- • compromised cognitive capacity
- • self-reported medical condition or medication use known to confound measures of systemic inflammation (e.g., autoimmune disorder, active infection)
About University Of California, Irvine
The University of California, Irvine (UCI) is a leading research institution renowned for its commitment to advancing health and medical knowledge through innovative clinical trials. With a robust infrastructure for clinical research, UCI fosters interdisciplinary collaboration among its esteemed faculty and researchers, aiming to translate scientific discoveries into effective therapeutic solutions. The university prioritizes ethical standards and participant safety while addressing critical healthcare challenges across various fields, including cancer, neurology, and public health. UCI's dedication to excellence in research and education positions it as a pivotal contributor to the advancement of clinical science and patient care.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Irvine, California, United States
Patients applied
Trial Officials
Michael A Hoyt, PhD
Principal Investigator
University of California, Irvine
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported